“I am often asked why we are focusing on nitric oxide as a treatment for coronavirus. The answer is simple: because we know it works.
A little history: in 1992, Science magazine named nitric oxide molecule of the year; tens of thousands of articles have been published on nitric oxide; and nitric oxide was the subject of a 1998 Nobel Prize in medicine.
We know nitric oxide works because it is part of the body’s natural defense system against viral infections. When a virus enters the body, our white blood cells produce nitric oxide to destroy the virus.
However, a viral infection can spread rapidly – more rapidly than the body can produce nitric oxide to combat it. Our approach is to supplement the body’s natural nitric oxide with additional nitric oxide that will be delivered by our drug, R-107.
The idea of delivering supplemental nitric oxide is not new. The problem, however, is that nitric oxide is a gas that must be administered as an inhalational therapy requiring special equipment and the assistance of a trained respiratory therapist.
We have found a way to make this remarkable drug available to patients in a practical manner. Our drug, R-107, is a nitric oxide-releasing liquid compound that can be taken orally in a capsule or by injection.
The importance of R-107 for the treatment of, and possibly also the prevention of, COVID-19 cannot be overstated. Unlike vaccines, that may lose effectiveness as the virus mutates, nitric oxide-releasing R-107 is expected to be a universal therapy against all COVID-19 strains, including those that are vaccine-resistant.
With R-107, we have found a way to supplement the body’s own nitric oxide defense system, and we can do this in a simple patient-friendly manner.”
Robert Farrell, Chairman, President and CEO
“We have found a way to make this remarkable drug available to patients in a practical manner”